Cargando…
Utility Values for Advanced Soft Tissue Sarcoma Health States from the General Public in the United Kingdom
Soft tissue sarcomas are a rare type of cancer generally treated with palliative chemotherapy when in the advanced stage. There is a lack of published health utility data for locally advanced “inoperable”/metastatic disease (ASTS), essential for calculating the cost-effectiveness of current and futu...
Autores principales: | Guest, Julian F., Sladkevicius, Erikas, Gough, Nicholas, Linch, Mark, Grimer, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613051/ https://www.ncbi.nlm.nih.gov/pubmed/23576896 http://dx.doi.org/10.1155/2013/863056 |
Ejemplares similares
-
Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
por: Guest, Julian F., et al.
Publicado: (2013) -
Utility values for specific hepatic encephalopathy health states elicited from the general public in the United Kingdom
por: Guest, Julian F, et al.
Publicado: (2014) -
Follow up after Primary Treatment of Soft Tissue Sarcoma: A Survey of Current Practice in the United Kingdom
por: Gerrand, C. H., et al.
Publicado: (2007) -
Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2014) -
Guidelines for the Management of Soft Tissue Sarcomas
por: Grimer, Robert, et al.
Publicado: (2010)